DOCSLIB.ORG

Treatment Strategies in Alzheimer's Disease: a Review with Focus On

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Treatment Strategies in Alzheimer's Disease: a Review with Focus On Biometals (2016) 29:827–839 DOI 10.1007/s10534-016-9959-8 Treatment strategies in Alzheimer’s disease: a review with focus on selenium supplementation Jan Aaseth . Jan Alexander . Geir Bjørklund . Knut Hestad . Petr Dusek . Per M. Roos . Urban Alehagen Received: 24 July 2016 / Accepted: 25 July 2016 / Published online: 16 August 2016 Ó The Author(s) 2016. This article is published with open access at Springerlink.com Abstract Alzheimer’s disease (AD) is a neurode- inhibition of enzymes responsible for its formation, or generative disorder presenting one of the biggest to promote resolution of existing cerebral Ab plaques. healthcare challenges in developed countries. No However, these approaches have failed to demonstrate effective treatment exists. In recent years the main significant cognitive improvements. Intracellular focus of AD research has been on the amyloid rather than extracellular events may be fundamental hypothesis, which postulates that extracellular precip- in AD pathogenesis. Selenate is a potent inhibitor of itates of beta amyloid (Ab) derived from amyloid tau hyperphosphorylation, a critical step in the precursor protein (APP) are responsible for the formation of neurofibrillary tangles. Some selenium cognitive impairment seen in AD. Treatment (Se) compounds e.g. selenoprotein P also appear to strategies have been to reduce Ab production through protect APP against excessive copper and iron J. Aaseth Á K. Hestad P. M. Roos (&) Department of Research, Innlandet Hospital Trust, Institute of Environmental Medicine, IMM, Karolinska Brumunddal, Norway Institutet, Nobels va¨g 13, Box 210, 17177 Stockholm, Sweden J. Aaseth Á K. Hestad e-mail: [email protected] Department of Public Health, Hedmark University of Applied Sciences, Elverum, Norway P. M. Roos Department of Clinical Physiology, St.Goran Hospital, J. Alexander Stockholm, Sweden Norwegian Institute of Public Health, Oslo, Norway U. Alehagen J. Alexander Division of Cardiovascular Medicine, Department of Norwegian University of Life Sciences (NMBU), Medical and Health Sciences, Linko¨ping University, A˚ s, Norway Linko¨ping, Sweden G. Bjørklund Council for Nutritional and Environmental Medicine, Mo i Rana, Norway P. Dusek Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic 123 828 Biometals (2016) 29:827–839 deposition. Selenoproteins show anti-inflammatory In the present paper, we first discuss treatment properties, and protect microtubules in the neuronal strategies based on traditional hypotheses of AD cytoskeleton. Optimal function of these selenoenzymes pathogenesis: (a) the transmitter hypothesis, (b) the requires higher Se intake than what is common in metabolic hypothesis, (c) the tau protein hypothesis, Europe and also higher intake than traditionally and (d) the amyloid cascade hypothesis. Then we recommended. Supplementary treatment with address the metal-based hypothesis of neuroinflam- N-acetylcysteine increases levels of the antioxidative mation which opens new therapeutic possibilities cofactor glutathione and can mediate adjuvant protec- (Ward et al. 2014). Oxidative stress from copper tion. The present review discusses the role of Se in AD (Cu) and iron (Fe) toxicity is implicated in the metal treatment and suggests strategies for AD prevention by hypothesis of AD pathogenesis. In this context we optimizing selenium intake, in accordance with the discuss a putative therapeutic or preventive role of metal dysregulation hypothesis. This includes in par- selenium (Se) supplementation, evoked by a Swedish ticular secondary prevention by selenium supplemen- study reporting improved vitality and reduced signs of tation to elderly with mild cognitive impairment. inflammation and oxidative stress after Se yeast and coenzyme Q10 intervention in an elderly population Keywords Alzheimer’s disease Á Copper Á Iron Á (Alehagen et al. 2013). Neuroinflammation Á Transmitters Á Selenium Traditional hypotheses Introduction The transmitter hypothesis Alzheimer’s disease (AD) is a neurodegenerative dis- Cholinergic neurons projecting to the hippocampus in order prevalent in old age. In developed countries 13 % the temporal lobe are affected early in AD. Deficient of people over 65 suffer from AD according to the spatial memory in rodents has been mapped to grid Alzheimer’s Association. Projected AD prevalence cells that collect sensory signals in the entorhinal indicate 100 million patients globally by 2050 (Alzhei- cortex (Hafting et al. 2005). The language problems mer’s 2015), leading to considerable economic burden and declining verbal recall characterizing AD patients for society and suffering for patients and caregivers. AD are presumed to arise from dysfunction in hippocam- is classified as genetic or sporadic. Genetic AD is an pal regions (Lim et al. 2012), and these cells are early-onset hereditary disease representing 1–2 % of influenced by cholinergic modulation (Konishi et al. diagnosed cases (Campion et al. 1999). In genetic AD 2015). Loss of cholinergic inputs to the hippocampus mutated genes coding for amyloid precursor protein is a well characterized abnormality in AD. Decreased (APP; chromosome 21) are found, and presenilin 1 acetylcholine release combined with reductions in (PS1; chromosome 14) and presenilin 2 (PS2; chromo- nicotinic and muscarinic receptors in the cortex and some 1), promote amyloid beta (Ab) formation. The hippocampus of AD brains examined post-mortem has vast majority of patients suffer from sporadic AD. been seen (Tata et al. 2014). Acetylcholinesterase Many sporadic AD patients are carriers of the e4 inhibitors used in AD treatment act by increasing allele of the ApoE gene (apolipoprotein E; chromo- acetylcholine bioavailability at synaptic loci. Unfor- some 19). The mechanism whereby ApoE e4 allele tunately, these enzyme inhibitors are not capable of increases AD risk is largely unknown (Hardy and reversing AD, nor slowing disease progression (Wal- Selkoe 2002). Recent research has unmasked minor lace and Bertrand 2013). Memantine acts on the mutations which mediate an intermediate AD risk. N-methyl-D-aspartate (NMDA) receptors blocking Most genes associated with AD roughly cluster within glutamate activity (Parsons et al. 2007). A dysfunction three metabolic pathways: lipid metabolism, inflam- of glutamatergic transmission has been hypothesized matory response, and endocytosis (Giri et al. 2016). to be involved in the neurodegeneration in AD. Aging is considered the principal risk factor for Memantine appears to improve this dysfunction, and sporadic AD, followed by hypertension, dyslipidemia, has been associated with a moderate decrease in metabolic syndrome and diabetes (Drachman 2014). clinical deterioration, with a small positive effect on 123 Biometals (2016) 29:827–839 829 cognition (Areosa et al. 2005). However, although (Yuraszeck et al. 2010). Derangements of microtubuli transmitter dysfunction is seen in AD, it can be and of the neuronal cytoskeleton provide clues to the suspected that the initial biochemical lesions involve understanding of AD pathogenesis. Intact microtubuli structural and functional impairment of vital proteins are involved in transport of essential substances from responsible for transmitter transport and neuronal neuronal bodies to synaptic structures. Phosphorylation integrity. regulates tau protein binding to microtubuli. Under physiological conditions the tau protein remains sol- The metabolic hypothesis uble, but hyperphosphorylation compromises its normal functions (Mehta et al. 2015), and leads to formation of Clinical studies suggest that the metabolic syndrome, insoluble neurofibrillary tangles, which are bundles of including hypertension, obesity, and insulin resistance paired helical protein filaments. Such excessive phos- or type 2 diabetes (T2DM), is a significant risk factor phorylation in AD must result from an imbalance for AD development (Kivipelto et al. 2005). Disturbed between phosphorylating kinases and de-phosphorylat- hippocampal insulin signalling is likely present in AD ing phosphatases. Increased expression of active (Hokama et al. 2014). Increased insulin resistance and kinases adjacent to neurofibrillary tangles has been oxidative stress with elevated levels of advanced described in AD (Hochgrafe et al. 2015). One of these glycation end products (AGE) are proposed mecha- kinases and a potential drug target is cyclin-dependent nisms by which metabolic syndrome may increase the kinase 5 (CDK5). Increased intracellular calcium in AD risk of AD (Li et al. 2012). A recent study in mice brains is associated with CDK5 activation (Shukla et al. indicated an association between amount of hypotha- 2012). CDK5 inhibitors have demonstrated neuropro- lamic beta-amyloid fragments, neuroinflammation tective properties in in vitro and in vivo AD models and peripheral glucose intolerance (Clarke et al. (Zimmer et al. 2012). Sodium selenate also reduces tau 2015). Reactive oxygen species (ROS) and tumor phosphorylation, both in cell cultures and in AD mouse necrosis factor alpha also contribute to this intriguing models (Corcoran et al. 2010b). Administration of syndrome combination (Lourenco et al. 2013). As the selenate to rodents produces cognitive improvements molecular mechanisms in AD and in insulin resistance and reduced neurodegeneration (van Eersel et al. 2010). seem related, it is tempting to assume that drugs used In these models selenate is presumably
Load more

Recommended publications
  • The Toxicology of Mercury Current Research and Emerging Trends
    Environmental Research 159 (2017) 545–554 Contents lists available at ScienceDirect Environmental Research journal homepage: www.elsevier.com/locate/envres The toxicology of mercury: Current research and emerging trends MARK ⁎ Geir Bjørklunda, , Maryam Dadarb, Joachim Mutterc, Jan Aasethd a Council for Nutritional and Environmental Medicine, Toften 24, 8610 Mo i Rana, Norway b Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran c Paracelsus Clinica al Ronc, Castaneda, Switzerland d Innlandet Hospital Trust and Inland Norway University of Applied Sciences, Elverum, Norway ARTICLE INFO ABSTRACT Keywords: Mercury (Hg) is a persistent bio-accumulative toxic metal with unique physicochemical properties of public Mercury health concern since their natural and anthropogenic diffusions still induce high risk to human and environ- Selenium mental health. The goal of this review was to analyze scientific literature evaluating the role of global concerns Thiols over Hg exposure due to human exposure to ingestion of contaminated seafood (methyl-Hg) as well as elemental Copper Hg levels of dental amalgam fillings (metallic Hg), vaccines (ethyl-Hg) and contaminated water and air (Hg Zinc chloride). Mercury has been recognized as a neurotoxicant as well as immunotoxic and designated by the World Toxicology Health Organization as one of the ten most dangerous chemicals to public health. It has been shown that the half- life of inorganic Hg in human brains is several years to several decades. Mercury occurs in the environment under different chemical forms as elemental Hg (metallic), inorganic and organic Hg. Despite the raising un- derstanding of the Hg toxicokinetics, there is still fully justified to further explore the emerging theories about its bioavailability and adverse effects in humans.
    [Show full text]
  • Molecular Targets of Manganese-Induced Neurotoxicity: a Five-Year Update
    International Journal of Molecular Sciences Review Molecular Targets of Manganese-Induced Neurotoxicity: A Five-Year Update Alexey A. Tinkov 1,2, Monica M. B. Paoliello 3,4, Aksana N. Mazilina 5, Anatoly V. Skalny 6,7, Airton C. Martins 3 , Olga N. Voskresenskaya 2 , Jan Aaseth 2,8 , Abel Santamaria 9, Svetlana V. Notova 10,11, Aristides Tsatsakis 2,12 , Eunsook Lee 13 , Aaron B. Bowman 14 and Michael Aschner 2,3,* 1 Laboratory of Ecobiomonitoring and Quality Control, Yaroslavl State University, 150003 Yaroslavl, Russia; [email protected] 2 Laboratory of Molecular Dietetics, Department of Neurological Diseases and Neurosurgery, Department of Analytical and Forensic Toxicology, IM Sechenov First Moscow State Medical University (Sechenov University), 119435 Moscow, Russia; [email protected] (O.N.V.); [email protected] (J.A.); [email protected] (A.T.) 3 Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA; [email protected] (M.M.B.P.); [email protected] (A.C.M.) 4 Graduate Program in Public Health, Center of Health Sciences, State University of Londrina, Londrina, PR 86038-350, Brazil 5 Department of Medical Elementology, Peoples’ Friendship University of Russia (RUDN University), 117198 Moscow, Russia; [email protected] 6 World-Class Research Center “Digital Biodesign and Personalized Healthcare”, IM Sechenov First Moscow State Medical University (Sechenov University), 119435 Moscow, Russia; [email protected] 7 Laboratory of Medical Elementology,
    [Show full text]
  • HANDBOOKS Published
    HANDBOOKS published: "Handbook on Toxicity of Inorganic Compounds" (ISBN: 0-8247-7727-1) edited by Hans G. Seiler, Helmut Sigel, and Astrid Sigel; Marcel Dekker, Inc.; New York, Basel; 1st published 1988; 3rd printing; 1069 pages 1. Scope and Use of the Handbook 14. Cadmium Helmut Sigel and Hans G. Seiler June K. Dunnick and Bruce A. Fowler 2. Bioinorganic Chemistry of Toxicity 15. Calcium R. Bruce Martin Nicholas J. Birch 3. General Aspects of Toxicology 16. Carbon John Savory, Roger L. Bertholf, and Hans R. Zorn, Werner F. Diller, Rainer Michael R. Wills Eisenmann, Klaus J. Freundt, Klaus D. Friedberg, Klaus Mengel, Rainer Schiele, 4. Some Recommendations for the Specimen and Gerhard Triebig Collection of Biological Materials for Analysis 17. Cesium Hans G. Seiler Robert J. Davie and Iain P. L. Coleman 5. Actinium 18. Chlorine Werner Burkart Ulrich Ewers, Nicolai Manojlovic, Wolfgang Hadnagy, and Yash Paul 6. Aluminum Grover Roger L. Bertholf, Michael R. Wills, and John Savory 19. Chromium Joshua W. Hamilton and 7. Antimony Karen E. Wetterhahn Rolf Iffland 20. Cobalt 8. Arsenic Jürgen Angerer and Regine Heinrich Wolfgang Arnold 21. Copper 9. Barium Bibudhendra Sarkar Gottfried Machata 22. Fluorine 10. Beryllium Guido Sticht Hans R. Zorn, Thomas W. Stiefel, Jörg Beuers, and Ronald Schlegelmilch 23. Gallium Raymond L. Hayes 11. Bismuth 24. Germanium David W. Thomas, T. F. Hartley, G. B. Gerber P. Coyle, and S. Sobecki 25. Gold 12. Boron Blaine M. Sutton and Lynn A. Larsen Michael J. DiMartino 13. Bromine 26. Hafnium Guido Sticht and Herbert Käferstein Martine Duverger-van Bogaert and Marie Lambotte-Vandepaer 26.
    [Show full text]
  • Dental Amalgam and Mercury
    Pharmacology & Toxicology 1992. 70, 308- 313. Dental Amalgam and Mercury Asbjorn J okstad", Yngvar TlIomassenl), Erik Byel), J ocelyne Clench. Ass'l and J an Aaseth"l 11Department of Anatomy, Dental Faculty, University of Oslo, P,Q Box 1052 Blindern, N·0316 Oslo 3. l!Nalional Institute of Occupational Health, Oslo, "\lorwegian Institule for Air Research, Lillestmm , and "Hedmark Central Ho>pital. Elverum. Norway • (Received October 21,1991: Ae<.:epted December 18. 1991) Ab~·lracr. The mercury concentrations in blood (HgB) and urine (HgU) samples, and in exhaled air (HgAir) were measured • in 147 individuals from an urban Norwegian populalion. using cold vapour atomic absorption spectrometry. The >tudy aimed to estimate the mercury exposure from the dental reslorations, hy correhlting the data 10 the presence of amalgam re>tor~tions . Mean values were HgB = 24.S nmoll1. HgU _ 17,5 nmolll and HgAir = O.S j.4glm', HgU correlated with HgAir. and both HgU and HgAir with the number of amalgam restoralions, amalgam restored surfaces and amalgam restored occlusal surfaces. 11gB sho,",'ed poor correlalion to HgU and HgAir and the presence of amalgam reslorations. A differenlialion of the mercury absorplion due lO exposure from dental amalgams and from the dietary intake, necessitates measurements of both organic and inorganic mercury in the pla,ma, and in the erYlhrocytes. The results suggesl that individuub with muny umalgam restoration:;, i.e., more lhan 36 restored surfaces, absorb 10 12 ~!g l'lglday. In order to estimate the impact of the exposure to mercury The consent permiHed one of the authors to oblain data on the in the cnvironment on general health it is necessary to dental status from lheir own dentiSls.
    [Show full text]
  • Sulfhydryl Groups As Targets of Mercury Toxicity
    Coordination Chemistry Reviews 417 (2020) 213343 Contents lists available at ScienceDirect Coordination Chemistry Reviews journal homepage: www.elsevier.com/locate/ccr Review Sulfhydryl groups as targets of mercury toxicity Olga P. Ajsuvakova a,b,c,1, Alexey A. Tinkov a,b,c,1, Michael Aschner c,d, João B.T. Rocha e, Bernhard Michalke f, Margarita G. Skalnaya a, Anatoly V. Skalny a,b,c, Monica Butnariu g,h, ⇑ Maryam Dadar i, Ioan Sarac g,h, Jan Aaseth c,j, Geir Bjørklund k, a Yaroslavl State University, Yaroslavl, Russia b Federal Scientific Center of Biological Systems and Agrotechnologies of the Russian Academy of Sciences, Orenburg, Russia c IM Sechenov First Moscow State Medical University, Moscow, Russia d Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY, USA e Departamento de Bioquímica e Biologia Molecular, CCNE, Universidade Federal de Santa Maria, Santa Maria, RS, Brazil f Helmholtz Zentrum München, Neuherberg, Germany g Banat’s University of Agricultural Sciences and Veterinary Medicine ‘‘King Michael I of Romania” from Timișoara, Timisßoara, Romania h CONEM Romania Biotechnology and Environmental Sciences Group, Banat’s University of Agricultural Sciences and Veterinary Medicine ‘‘King Michael I of Romania” from Timișoara, Timisßoara, Romania i Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran j Research Department, Innlandet Hospital Trust, Brumunddal, Norway k Council for Nutritional and Environmental Medicine (CONEM), Mo i Rana, Norway article info abstract Article history: The present study addresses existing data on the affinity and conjugation of sulfhydryl (thiol; -SH) groups Received 4 February 2020 of low- and high-molecular-weight biological ligands with mercury (Hg).
    [Show full text]
  • Prevention of Progression in Parkinson's Disease
    Biometals (2018) 31:737–747 https://doi.org/10.1007/s10534-018-0131-5 (0123456789().,-volV)(0123456789().,-volV) Prevention of progression in Parkinson’s disease Jan Aaseth . Petr Dusek . Per M. Roos Received: 20 June 2018 / Accepted: 11 July 2018 / Published online: 20 July 2018 Ó The Author(s) 2018 Abstract Environmental influences affecting genet- compounds known to decrease PD risk including ically susceptible individuals seem to contribute caffeine, niacin, nicotine and salbutamol also possess significantly to the development of Parkinson’s dis- iron binding properties. Adequate function of antiox- ease (PD). Xenobiotic exposure including transitional idative mechanisms in the vulnerable brain cells can metal deposition into vulnerable CNS regions appears be restored by acetylcysteine supplementation to to interact with PD genes. Such exposure together with normalize intracellular glutathione activity. Other mitochondrial dysfunction evokes a destructive cas- preventive measures to reduce deterioration of cade of biochemical events, including oxidative stress dopaminergic neurons may involve life-style changes and degeneration of the sensitive dopamine (DA) such as intake of natural antioxidants and physical production system in the basal ganglia. Recent exercise. Further research is recommended to identify research indicates that the substantia nigra degenera- therapeutic targets of the proposed interventions, in tion can be decelerated by treatment with iron binding particular protection of the DA biosynthesis by oxygen compounds such as deferiprone. Interestingly radical scavengers and iron binding agents. J. Aaseth P. M. Roos (&) Research Department, Innlandet Hospital Trust, Institute of Environmental Medicine, Karolinska Brumunddal, Norway Institutet, Solna, Sweden e-mail: [email protected] J. Aaseth Inland Norway University of Applied Sciences, Elverum, P.
    [Show full text]
  • Handbook on the Toxicology of Metals Job Name: 201299T Job Name: 201299T
    Job Name: 201299t Handbook on the Toxicology of Metals Job Name: 201299t Job Name: 201299t Handbook on the Toxicology of Metals Third Edition Editors: Gunnar F. Nordberg Bruce A. Fowler Monica Nordberg Lars T. Friberg Editorial Committee: Antero Aitio Ingvar Andersson Bruce A. Fowler Lars T. Friberg Gunnar F. Nordberg Monica Nordberg Peter Pärt Staffan Skerfving AMSTERDAM • BOSTON • HEIDELBERG • LONDON NEW YORK • OXFORD • PARIS • SAN DIEGO SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO Academic press is an imprint of Elsevier Job Name: 201299t Academic Press is an imprint of Elsevier 30 Corporate Drive, Suite 400, Burlington, MA 01803, USA 525 B Street, Suite 1900, San Diego, California 92101-4495, USA 84 Theobald’s Road, London WC1X 8RR, UK This book is printed on acid-free paper. Copyright © 2007, 1986, Elsevier B.V. All rights reserved. Except for Chapter 29 which is in the public domain. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher. Permissions may be sought directly from Elsevier’s Science &Technology Rights Department in Oxford, UK: phone: (+44) 1865 843830, fax: (+44) 1865 853333, E-mail: [email protected]. You may also complete your request online via the Elsevier homepage (http://elsevier.com), by selecting “Support & Contact” then “Copyright and Permission” and then “Obtaining Permissions.” Library of Congress Cataloging-in-Publication Data Handbook on the toxicology of metals / editors, Gunnar F. Nordberg … [et al.]. — 3rd ed. p. ; cm. Includes bibliographical references and index.
    [Show full text]
  • A Review on Coordination Properties of Thiol-Containing Chelating Agents Towards Mercury, Cadmium, and Lead
    molecules Review A Review on Coordination Properties of Thiol-Containing Chelating Agents Towards Mercury, Cadmium, and Lead Geir Bjørklund 1,* , Guido Crisponi 2 , Valeria Marina Nurchi 3 , Rosita Cappai 3, Aleksandra Buha Djordjevic 4 and Jan Aaseth 5,6,7,* 1 Council for Nutritional and Environmental Medicine, N-8610 Mo i Rana, Norway 2 Cittadella Universitaria, University of Cagliari, 09042 Cagliari, Italy 3 Department of Life and Environmental Sciences, University of Cagliari, 09042 Cagliari, Italy 4 Department of Toxicology “Akademik Danilo Soldatovi´c”,Faculty of Pharmacy, University of Belgrade, 11000 Belgrade, Serbia 5 Research Department, Innlandet Hospital, N-2380 Brumunddal, Norway 6 Inland Norway University of Applied Sciences, N-2411 Elverum, Norway 7 IM Sechenov First Moscow State Medical University (Sechenov University), 119146 Moscow, Russia * Correspondence: [email protected] (G.B.); [email protected] (J.A.) Academic Editor: Erika Ferrari Received: 24 July 2019; Accepted: 31 August 2019; Published: 6 September 2019 Abstract: The present article reviews the clinical use of thiol-based metal chelators in intoxications and overexposure with mercury (Hg), cadmium (Cd), and lead (Pb). Currently, very few commercially available pharmaceuticals can successfully reduce or prevent the toxicity of these metals. The metal chelator meso-2,3-dimercaptosuccinic acid (DMSA) is considerably less toxic than the classical agent British anti-Lewisite (BAL, 2,3-dimercaptopropanol) and is the recommended agent in poisonings with Pb and organic Hg. Its toxicity is also lower than that of DMPS (dimercaptopropane sulfonate), although DMPS is the recommended agent in acute poisonings with Hg salts. It is suggested that intracellular Cd deposits and cerebral deposits of inorganic Hg, to some extent, can be mobilized by a combination of antidotes, but clinical experience with such combinations are lacking.
    [Show full text]
  • The Neurotoxicity of Iron, Copper and Manganese in Parkinson's And
    G Model JTEMB-25537; No. of Pages 11 ARTICLE IN PRESS Journal of Trace Elements in Medicine and Biology xxx (2014) xxx–xxx Contents lists available at ScienceDirect Journal of Trace Elements in Medicine and Biology jou rnal homepage: www.elsevier.de/jtemb 10th NTES Symposium Review The neurotoxicity of iron, copper and manganese in Parkinson’s and Wilson’s diseases a,b,∗ c,d e f Petr Dusek , Per M. Roos , Tomasz Litwin , Susanne A. Schneider , g h Trond Peder Flaten , Jan Aaseth a Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague, Czech Republic b Institute of Neuroradiology, University Medicine Göttingen, Göttingen, Germany c Department of Neurology, Division of Clinical Neurophysiology, Oslo University Hospital, Oslo, Norway d Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden e 2nd Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland f Neurology Department, University of Kiel, Kiel, Germany g Department of Chemistry, Norwegian University of Science and Technology, Trondheim, Norway h Department of Medicine, Innlandet Hospital Trust, Kongsvinger Hospital Division, Kongsvinger, Norway a r t i c l e i n f o a b s t r a c t Article history: Impaired cellular homeostasis of metals, particularly of Cu, Fe and Mn may trigger neurodegeneration Received 31 January 2014 through various mechanisms, notably induction of oxidative stress, promotion of ␣-synuclein aggrega- Accepted 22 May 2014 tion and fibril formation, activation of microglial cells leading to inflammation and impaired production of metalloproteins. In this article we review available studies concerning Fe, Cu and Mn in Parkinson’s Keywords: disease and Wilson’s disease.
    [Show full text]
  • Selenium and Coenzyme Q10 Interrelationship in Cardiovascular Diseases - a Clinician's Point of View
    Selenium and coenzyme Q10 interrelationship in cardiovascular diseases - A clinician's point of view Urban Alehagen and Jan Aaseth Linköping University Post Print N.B.: When citing this work, cite the original article. Original Publication: Urban Alehagen and Jan Aaseth, Selenium and coenzyme Q10 interrelationship in cardiovascular diseases - A clinician's point of view, 2015, Journal of Trace Elements in Medicine and Biology, (31), 157-162. http://dx.doi.org/10.1016/j.jtemb.2014.11.006 Copyright: Elsevier http://www.elsevier.com/ Postprint available at: Linköping University Electronic Press http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-113917 1 Selenium and Coenzyme Q10 interrelationship in cardiovascular diseases- a clinician´s point of view. Urban Alehagen1 and Jan Aaseth2 1: Division of Cardiovascular Medicine, Department of Medicine and Health Sciences, Faculty of Health Sciences, Linköping University, Department of Cardiology UHL, County Council of Östergötland, Linköping, Sweden 2: Department of Medicine, Innlandet Hospital Trust, Norway Corresponding author: Urban Alehagen, Kard klin, Universitetssjukhuset I Linköping, SE-58185 Linköping, Sweden , e-mail: [email protected] Jan Aaseth, Dept of Medicine, Innlandet Hospital Trust, N- 2226 Kongsvinger, Norway Running title: Ubiquinone and selenium Financial disclosure: None to report. 2 Abstract A short review is given of the potential role of selenium deficiency and selenium intervention trials in atherosclerotic heart disease. Selenium is an essential constituent of several proteins, including the glutathione peroxidases and selenoprotein P. The selenium intake in Europe is generally in the lower margin of recommendations from authorities. Segments of populations in these areas may thus have a deficient intake that may be presented by a deficient anti-oxidative capacity in various illnesses, in particular atherosclerotic disease, and this may influence the prognosis of the process.
    [Show full text]
  • Chelator Combination As Therapeutic Strategy in Mercury and Lead Poisonings ⇑ Jan Aaseth A,B, Olga P
    Coordination Chemistry Reviews 358 (2018) 1–12 Contents lists available at ScienceDirect Coordination Chemistry Reviews journal homepage: www.elsevier.com/locate/ccr Review Chelator combination as therapeutic strategy in mercury and lead poisonings ⇑ Jan Aaseth a,b, Olga P. Ajsuvakova c, Anatoly V. Skalny d,e,f, Margarita G. Skalnaya d, Alexey A. Tinkov d,f,g, a Innlandet Hospital Trust, 2226 Kongsvinger, Norway b Inland Norway University of Applied Sciences, Terningen Arena, 2411 Elverum, Norway c All-Russian Research Institute of Phytopathology, Institute, 5, Bolshie Vyazemy, Odintsovo district, Moscow region, 143050, Russia d Peoples’ Friendship University of Russia (RUDN University), Miklukho-Maklay St., 10/2, Moscow 117198, Russia e Orenburg State University, Pobedy Ave., 13, Orenburg 460018, Russia f Yaroslavl State University, Sovetskaya St., 14, Yaroslavl 150000, Russia g Institute of Cellular and Intracellular Symbiosis, Russian Academy of Sciences, Orenburg 460008, Russia article info abstract Article history: The chelating thiols dimercaptosuccinate (DMSA) and dimercaptopropane sulfonate (DMPS) are effective Received 22 August 2017 in enhancing urinary excretion of mercury and lead. However, strategies for mobilization of toxic metals Accepted 15 December 2017 from aged brain deposits may require combined use of a water soluble agent, removing circulating metal into urine, as well as lipophilic chelator, being used to facilitate the brain-to-blood mobilization. Pb(II) and Hg(II) ions are coordinated with DMSA through one ACOOH and one SH group. However Pb(II) Keywords: can bind with racemic DMSA through two SH groups in non-aqueous solvents (when ACOOH groups Mercury are esterified). Generally, such Pb(II) and Hg(II) complexes have a composition of 1:1 and 1:2.
    [Show full text]
  • Chronic Fatigue Syndrome (CFS): Suggestions for a Nutritional Treatment in the Therapeutic Approach T ⁎ Geir Bjørklunda, , Maryam Dadarb, Joeri J
    Biomedicine & Pharmacotherapy 109 (2019) 1000–1007 Contents lists available at ScienceDirect Biomedicine & Pharmacotherapy journal homepage: www.elsevier.com/locate/biopha Review Chronic fatigue syndrome (CFS): Suggestions for a nutritional treatment in the therapeutic approach T ⁎ Geir Bjørklunda, , Maryam Dadarb, Joeri J. Penc,d, Salvatore Chirumboloe, Jan Aasethf,g a Council for Nutritional and Environmental Medicine, Mo i Rana, Norway b Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran c Diabetes Clinic, Department of Internal Medicine, UZ Brussel, Vrije Universiteit Brussel (VUB), Brussels, Belgium d Department of Nutrition, UZ Brussel, Vrije Universiteit Brussel (VUB), Brussels, Belgium e Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy f Research Department, Innlandet Hospital Trust, Brumunddal, Norway g Inland Norway University of Applied Sciences, Elverum, Norway ARTICLE INFO ABSTRACT Keywords: Chronic fatigue syndrome (CFS) is known as a multi-systemic and complex illness, which induces fatigue and Chronic fatigue syndrome long-term disability in educational, occupational, social, or personal activities. The diagnosis of this disease is Nutrients difficult, due to lacking a proper and suited diagnostic laboratory test, besides to its multifaceted symptoms. Immunoglobulins Numerous factors, including environmental and immunological issues, and a large spectrum of CFS symptoms, Cytokines have recently been reported. In this review, we focus on the nutritional intervention in CFS, discussing the many Lymphocyte transformation immunological, environmental, and nutritional aspects currently investigated about this disease. Changes in Delayed hypersensitivity immunoglobulin levels, cytokine profiles and B- and T- cell phenotype and declined cytotoxicity of natural killer cells, are commonly reported features of immune dysregulation in CFS.
    [Show full text]